SCHEMBL24678431

SCHEMBL24678431

CCSC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
TDP1 Q9NUW8 3/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
MAPK1 P28482 2/20 0.52
KMT2A Q03164 2/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
LMNA P02545 3/20 0.47
HCAR2 Q8TDS4 1/20 0.47
IDO1 P14902 1/20 0.46
RAB9A P51151 3/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
STAT1 P42224 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5989265 0.86 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL29325681 0.84 ALDH1A1 (0.49) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL1722103 0.83 IDO1 (0.65) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL16348281 0.81 ALDH1A1 (0.53) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL12189905 0.81 ALDH1A1 (0.62) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL26726536 0.81 ALDH1A1 (0.53) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL30311836 0.80 ALDH1A1 (0.61) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL9646712 0.80 ALDH1A1 (0.61) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL21332538 0.80 CETP (0.46) ALDH1A1TDP1L3MBTL1MAPK1KMT2A
SCHEMBL19588437 0.80 ALDH1A1 (0.51) ALDH1A1TDP1L3MBTL1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11732093-B2 Cross polymers composed of polysaccharides and polyamino acids, and uses thereof POLYPEPTIDE THERAPEUTIC SOLUTIONS S.L. (ES) 2023-08-22 US disclosed
US-20230125434-A1 METHOD FOR PRODUCING MONOSULFOXIDE DERIVATIVE KUMIAI CHEMICAL INDUSTRY CO. LTD. (JP) 2023-04-27 US disclosed
WO-2022224164-A1 GLUCAGON LIKE PEPTIDE COMPOUNDS NOVARTIS AG (CH) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125434-A1 METHOD FOR PRODUCING MONOSULFOXIDE DERIVATIVE TST, STS, MPST ALDH1A1 392/4885TDP1 4641/4885L3MBTL1 4263/4885
US-11732093-B2 Cross polymers composed of polysaccharides and polyamino acids, and uses thereof CD44, CUTA, PARG ALDH1A1 2246/4885TDP1 2738/4885L3MBTL1 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.